A Phase I Study of the Safety and Pharmacokinetics of Higher-Dose Icotinib in Patients With Advanced Non-Small Cell Lung Cancer

LESSONS LEARNED: This phase I study evaluated the maximum tolerated dose, dose-limiting toxicities, safety, pharmacokinetics, and efficacy of icotinib with a starting dose of 250 mg in pretreated, advanced non-small cell lung cancer patients. We observed a maximum tolerated dose of 500 mg with a fav...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Oncologist
Autori principali: Liu, Jian, Wu, Lihua, Wu, Guolan, Hu, Xingjiang, Zhou, Huili, Chen, Junchun, Zhu, Meixiang, Xu, Wei, Tan, Fenlai, Ding, Lieming, Wang, Yinxiang, Shentu, Jianzhong
Natura: Artigo
Lingua:Inglês
Pubblicazione: AlphaMed Press 2016
Soggetti:
Clinical Trial Results
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5189627/
https://ncbi.nlm.nih.gov/pubmed/27789778
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2016-0256
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi